Results 241 to 250 of about 6,667,826 (304)

Residual disease after neoadjuvant therapy in HER2-positive breast cancer: biology, burden, or both? [PDF]

Transl Cancer Res
Di Lena É, Takabe K.
europepmc   +1 more source

The impact of leukocyte‐associated RNA retention on platelet RNA‐based cancer detection

Molecular Oncology, EarlyView.
Platelets carry RNA signals that may help detect cancer, but platelet samples can also retain RNA from white blood cells. We found that this retained white blood cell signal did not significantly affect machine learning cancer classification, suggesting that the cancer‐related RNA signal in platelets is largely independent of leukocyte‐associated RNA ...
Michał Sieczczyński, Krzysztof Pastuszak, Anna Samelak‐Czajka, Zuzanna Cemka, Paulina Jackowiak, Tomasz Stefaniak, Sylwia Łapińska‐Szumczyk, Jacek Jassem, Anna J. Żaczek, Matthew T. Rondina, Myron G. Best, Sjors G. J. G. In 't Veld, Anna Supernat   +12 more
wiley   +1 more source

HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma. [PDF]

Br J Haematol
Hughes E, Blombery P, Kannan S, Khong T, Spencer A, Morley A.   +5 more
europepmc   +1 more source

Vascular normalization confers an endothelial immune suppressive gene expression profile

Molecular Oncology, EarlyView.
We compare the immunoregulatory gene expression profiles of healthy endothelial cells or endothelial cells from tumors having a normalized endothelium (low leakage) with that of wild‐type tumors (high leakage) and observe that the wild‐type tumor endothelium exhibits immunostimulatory properties.
Liqun He, Michael Welsh
wiley   +1 more source

Insights into ctDNA assessment to detect minimal residual disease (MRD) in localized colorectal cancer. [PDF]

Sci Rep
Labiano I, Guerrero-Setas D, Huerta AE, Mata E, Alkorta-Aranburu G, Ordoñez GR, Berraondo P, Lecumberri A, Ochoa P, Caseda I, Termini R, Agirre-Mikelarena B, Amat I, Castro N, Arasanz H, Alsina M, Vera R.   +16 more
europepmc   +1 more source

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

Molecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis, Tereza Buchtová, Jirina Bartkova, Marie Lund Bay, Christoffer Lynge Halvorsen, Zuzana Machacova, Zdenek Skrott, Martin Mistrik, Ekaterina Dulina, Miguel Andujar‐Sanchez, Estrid Høgdall, Tine Henrichsen Schnack, Claus Høgdall, Berit Jul Mosgaard, Marie Boennelycke, Jacob Brink Laursen, Allan Jensen, Susanne K. Kjær, Tuula Kallunki, Robert Strauss, Jiri Bartek   +20 more
wiley   +1 more source

A streamlined hybrid-capture and genome-wide multi-omic platform for highly sensitive ctDNA minimal residual disease monitoring. [PDF]

J Liq Biopsy
Nguyen T, Nguyen Hoang VA, Huynh C, Nguyen V, Le SH, Trac QT, Nguyen Hoang TP, Dao NA, Nguyen MTB, Tran NH, Phan DM, Giang H, Nguyen HN, Tu LN.   +13 more
europepmc   +1 more source

An outer membrane vesicle‐associated two‐track model for enterotoxigenic Bacteroides fragilis oncogenesis

Molecular Oncology, EarlyView.
Enterotoxigenic Bacteroides fragilis is a gut bacterium linked to bowel cancer. We propose that its toxin acts along two routes: at the cell surface, cutting the adhesion protein E‐cadherin and triggering inflammation; and inside the cell, delivered by bacterial vesicles, switching on NOD1 and cancer stem cell programs.
Kangchan Choi, Sang‐Hyeon Yoo, Ki‐Jong Rhee   +2 more
wiley   +1 more source

Circulating Tumor DNA for Minimal Residual Disease Detection and Recurrence Prediction in Upper Gastrointestinal Cancers: A Scoping Review. [PDF]

J Clin Med
Hadjigeorgiou L, Yerolatsite M, Torounidou N, Zarkavelis G, Schizas D, Tatsis V, Rausei S, Vlachos K, Lianos GD.   +8 more
europepmc   +1 more source

Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient Management. [PDF]

Cancers (Basel)
Kim J, Morceau F, Kwon YJ, Shin YJ.
europepmc   +1 more source